Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Long term survivors in the era of immunotherapy of cancer

Ideal duration of IT: How to define it and what are the implications

Date

23 Oct 2023

Session

Long term survivors in the era of immunotherapy of cancer

Topics

Cancer Biology; Translational Research; Immunotherapy

Tumour Site

Melanoma

Presenters

Teresa Amaral

Authors

T.M.S. Amaral

Author affiliations

Dermato-oncology Department, Skin Cancer Clinical Trials Center, University of Tuebingen, Tübingen/DE

Resources

This content is available to ESMO members and event participants.

Login

Resources from the same session

23 Oct 2023

Long-term toxicity of immunotherapeutics

Presenter: David McDermott

Session: Long term survivors in the era of immunotherapy of cancer

Resources:

Slides

Webcast

23 Oct 2023

Quality of life in IO-treated long-term survivors

Presenter: Lonneke Van De Poll-franse

Session: Long term survivors in the era of immunotherapy of cancer

Resources:

Slides

Webcast

23 Oct 2023

Cognitive defects in long term IO

Presenter: Anne Rogiers

Session: Long term survivors in the era of immunotherapy of cancer

Resources:

Slides

Webcast

23 Oct 2023

Discussion

Presenter: All Speakers

Session: Long term survivors in the era of immunotherapy of cancer

Resources:

Slides

Webcast